132335-48-9Relevant academic research and scientific papers
Anti-depression of the raw material preparation method
-
Paragraph 0020; 0021, (2018/07/15)
The present invention discloses an anti-depression drug duloxetine hydrochloride - process improvement and optimization, which belongs to the field of biological medicine. Comprises the following main features: a) used in the Mannich reaction in N - methyl benzylamine hydrochloride, without the use of dimethylamine hydrochloride, so that the follow-up steps in the dealkylation reaction effect is better, yield is higher; b) without using any expensive chiral catalyst or a phase transfer catalyst, to use with high stability and high catalytic performance of metal catalyst; c) the better solvent for crystallization and to the solvent method, to avoid the harm of the residual solvent for crystallization; d) splitting the chiral compound in the dealkylation after, adopts a unique recrystallization technology, will split the mixture after separation, purity and relatively easy to assemble and disassemble the luminosity (S)- N - methyl - 3 - (1 - naphthoxy) - 3 - (2 - thienyl) propylamine/tartrate, so that the resulting duloxetine hydrochloride product can achieve a better therapeutic effect. The process of the invention clear, simple and convenient operation, mild reaction conditions, low production cost, is extremely beneficial to industrial production.
PEG 400/cerium ammonium nitrate combined with microwave-assisted synthesis for rapid access to beta-amino ketones. an easy-to-use protocol for discovering new hit compounds
Rossino, Giacomo,Raimondi, Maria Valeria,Rui, Marta,Di Giacomo, Marcello,Rossi, Daniela,Collina, Simona
, (2018/04/06)
Compound libraries are important requirement in target-based drug discovery. In the present work, a small focused compound library based on β-aminoketone scaffold has been prepared combining microwave-assisted organic synthesis (MAOS) with polymer-assiste
ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT
-
Paragraph 0030; 0163, (2013/03/28)
Aralkyl diamine derivative of the following formula, pharmaceutically acceptable salts or uses thereof as antidepressants. The derivatives have triplex inhibiting activities of the reuptake of 5-HT, dopamine and noradrenalin, which can be administered to the patients in need of such treatment in the form of compositions orally or injectedly et al.
PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME
-
Page/Page column 46, (2012/11/08)
The present invention relates to: a ketone compound having transglutaminase-inhibiting activity, which is represented by the following Formula 1, 2, or 3: wherein R1 is a substituted or unsubstituted aryl or heterocyclyl group, R2, R3, and R4 are hydrogen atoms, n is 2, X is halogen, R5 and R6 independently represent a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl, aryl, or aralkyl group, wherein R5 and R6 are not hydrogen atoms at the same time, or R5 and R6 may be taken together to form a saturated or unsaturated and substituted or unsubstituted heterocyclyl group containing a nitrogen atom (N); an inhibitor of protein crosslinking comprising the compound; and a composition for preventing or treating a protein-crosslinking causative disease, which comprises the compound or the protein crosslinking inhibitor.
